<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1004" relname="span">Triple-negative breast cancer</segment>
<segment id="3" parent="2" relname="restatement">( TNBC )</segment>
<segment id="4" parent="1003" relname="same_unit">is a heterogeneous disease ,</segment>
<segment id="5" parent="1005" relname="span">characterized by aggressive clinical behavior , poor prognosis , a significantly increased risk of relapse , and shorter survival rates than patients</segment>
<segment id="6" parent="5" relname="elaboration">affected by other molecular subtypes of breast cancer .</segment>
<segment id="7" parent="1007" relname="span">TNBC is clinically defined as tumors</segment>
<segment id="8" parent="1008" relname="span">that lack expression of the estrogen receptor</segment>
<segment id="9" parent="8" relname="elaboration">( ER ) ,</segment>
<segment id="10" parent="1011" relname="span">progesterone receptor</segment>
<segment id="11" parent="10" relname="elaboration">( PR ) ,</segment>
<segment id="12" parent="1001" relname="joint">and HER2 amplification .</segment>
<segment id="13" parent="1001" relname="joint">It affects primarily younger premenopausal women</segment>
<segment id="14" parent="1014" relname="span">and tends to have higher incidences in African American women ,</segment>
<segment id="15" parent="1015" relname="span">although recent studies reported no differences in clinical outcomes between Caucasian and African American women</segment>
<segment id="16" parent="15" relname="circumstance">after adjusting for socioeconomic factors .</segment>
<segment id="17" parent="1017" relname="preparation">Currently , there are no effective targeted therapies .</segment>
<segment id="18" parent="1017" relname="joint">Cytotoxic chemotherapy remains the only effective therapeutic modality for this aggressive and often lethal type of breast cancer .</segment>
<segment id="19" parent="1019" relname="span">Therefore , there is an urgent need for the discovery of molecular markers and targets for the development of novel targeted therapeutics .</segment>
<segment id="20" parent="1020" relname="joint">Our understanding of the molecular basis of TNBC</segment>
<segment id="21" parent="1020" relname="joint">and development of effective targeted therapies has been hampered by the complexity and multifactorial etiology of the disease .</segment>
<segment id="22" parent="1017" relname="joint">Genes play a major role in the pathogenesis of TNBC .</segment>
<segment id="23" parent="1017" relname="joint">The majority of TNBC patients carry mutations in the highly penetrant cancer susceptibility genes BRCA1 and BRCA2 .</segment>
<segment id="24" parent="1024" relname="span">In unselected TNBC cases , the prevalence of pathogenic germline BRCA1 and BRCA2 mutations is approximately twice as high as in breast cancer overall .</segment>
<segment id="25" parent="24" relname="elaboration">Apart from BRCA1 and BRCA2 , the rarely mutated breast cancer predisposition genes PALB2 and FANCM have been associated with TNBC .</segment>
<segment id="26" parent="1026" relname="span">Multigene panel testing has also identified genes with high and moderate penetrance</segment>
<segment id="27" parent="1027" relname="span">associated with an increased risk</segment>
<segment id="28" parent="27" relname="elaboration">of developing TNBC .</segment>
<segment id="29" parent="1017" relname="joint">However ,</segment>
<segment id="30" parent="1030" relname="concession">although genes may play a strong role ,</segment>
<segment id="31" parent="32" relname="attribution">molecular epidemiology studies suggest</segment>
<segment id="32" parent="1031" relname="span">that TNBC risk is largely determined by interactions between genes and environment .</segment>
<segment id="33" parent="1033" relname="span">Increased attention has focused on epigenetic variation such as DNA methylation and TNBC</segment>
<segment id="34" parent="33" relname="cause">because enduring epigenetic landmarks define the tumor microenvironment .</segment>
<segment id="35" parent="1035" relname="preparation">Moreover ,</segment>
<segment id="36" parent="1036" relname="preparation">because DNA methylation regulates gene expression ,</segment>
<segment id="37" parent="1037" relname="preparation">aberrant methylated genes could serve as complementary diagnostic tools , prognostic markers and predictors of response to treatment .</segment>
<segment id="38" parent="1039" relname="span">Thus , a critical knowledge gap , and an unmet medical need , is understanding the interplay between genetic</segment>
<segment id="39" parent="38" relname="elaboration">( both germline and somatic )</segment>
<segment id="40" parent="1038" relname="same_unit">variation and epigenomic variation in TNBC .</segment>
<segment id="41" parent="1037" relname="joint">Advances in microarray technology have enabled molecular classification of subtypes of TNBC .</segment>
<segment id="42" parent="1044" relname="span">At least , several clinically validated prognostic assays</segment>
<segment id="43" parent="42" relname="elaboration">including the Prosigna PAM50 , MammaPrint and Oncotype DX , have been developed</segment>
<segment id="44" parent="1044" relname="means">using transcription profiling .</segment>
<segment id="45" parent="1045" relname="same_unit">However ,</segment>
<segment id="46" parent="1047" relname="concession">although these primary analyses have been successful</segment>
<segment id="47" parent="1048" relname="concession">in identifying prognostic markers ,</segment>
<segment id="48" parent="1048" relname="span">they have been unsuccessful</segment>
<segment id="49" parent="48" relname="circumstance">in establishing the causal association between gene expression and the disease .</segment>
<segment id="50" parent="1050" relname="span">High-throughput genotyping</segment>
<segment id="51" parent="1053" relname="span">using genome-wide association studies</segment>
<segment id="52" parent="51" relname="restatement">( GWAS )</segment>
<segment id="53" parent="1052" relname="same_unit">has enabled discovery of genetic variants</segment>
<segment id="54" parent="1054" relname="span">associated with an increased risk</segment>
<segment id="55" parent="54" relname="elaboration">of developing TNBC .</segment>
<segment id="56" parent="1057" relname="span">The recent surge of next generation sequencing of tumor genomes by large multicenter projects , such as The Cancer Genome Atlas</segment>
<segment id="57" parent="56" relname="restatement">( TCGA )</segment>
<segment id="58" parent="1059" relname="span">and the International Cancer Genome Consortium</segment>
<segment id="59" parent="58" relname="elaboration">( ICGC ) ,</segment>
<segment id="60" parent="1060" relname="span">have generated comprehensive catalogues of somatic mutations</segment>
<segment id="61" parent="60" relname="elaboration">associated with TNBC .</segment>
<segment id="62" parent="1037" relname="joint">The clonal and mutational spectrum of primary TNBCs have also been characterized .</segment>
<segment id="63" parent="1063" relname="span">We recently reported oncogenic interactions between genes</segment>
<segment id="64" parent="63" relname="elaboration">containing germline and somatic mutations in TNBC .</segment>
<segment id="65" parent="1064" relname="joint">However , to date , information on germline , somatic and gene expression variation has not been leveraged</segment>
<segment id="66" parent="1066" relname="span">and integrated with DNA methylation data</segment>
<segment id="67" parent="66" relname="purpose">to map the interplay between genetic and epigenetic variation in TNBC .</segment>
<segment id="68" parent="1068" relname="span">This limited progress must be balanced against the recognition</segment>
<segment id="69" parent="1069" relname="span">that genomic and epigenomic alterations have long been considered as two separate molecular mechanisms</segment>
<segment id="70" parent="69" relname="elaboration">participating in TNBC pathogenesis .</segment>
<segment id="71" parent="1064" relname="joint">The objective of this investigation is to deconvolute the genomic and epigenomic interaction landscape ,</segment>
<segment id="72" parent="1072" relname="span">and to discover and characterize the molecular networks and signaling pathways</segment>
<segment id="73" parent="72" relname="elaboration">perturbed by these interactions in TNBC .</segment>
<segment id="74" parent="1075" relname="attribution">Our working hypothesis was</segment>
<segment id="75" parent="1076" relname="span">that TNBC originates from a complex interplay between genomic</segment>
<segment id="76" parent="75" relname="elaboration">( both germline and somatic )</segment>
<segment id="77" parent="1075" relname="same_unit">variation and epigenomic variations .</segment>
<segment id="78" parent="1079" relname="attribution">We further hypothesized</segment>
<segment id="79" parent="1079" relname="span">that these complex arrays of interacting genomic and epigenomic factors affect entire molecular networks and signaling pathways</segment>
<segment id="80" parent="79" relname="elaboration">which , in turn , drive TNBC .</segment>
<segment id="81" parent="1080" relname="span">We addressed these hypotheses</segment>
<segment id="82" parent="1081" relname="span">by integrating information on germline variation from GWAS with information on somatic and epigenomic variation from TCGA</segment>
<segment id="83" parent="82" relname="elaboration">using gene expression as the intermediated phenotype .</segment>
<group id="1000" type="span" />
<group id="1001" type="multinuc" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1001" relname="joint"/>
<group id="1003" type="multinuc" parent="1002" relname="span"/>
<group id="1004" type="span" parent="1003" relname="same_unit"/>
<group id="1005" type="span" parent="1003" relname="elaboration"/>
<group id="1007" type="span" parent="1001" relname="joint"/>
<group id="1008" type="span" parent="7" relname="elaboration"/>
<group id="1011" type="span" parent="1001" relname="joint"/>
<group id="1014" type="span" parent="1001" relname="joint"/>
<group id="1015" type="span" parent="14" relname="concession"/>
<group id="1016" type="span" parent="1001" relname="joint"/>
<group id="1017" type="multinuc" parent="1016" relname="span"/>
<group id="1019" type="span" parent="1017" relname="joint"/>
<group id="1020" type="multinuc" parent="19" relname="elaboration"/>
<group id="1024" type="span" parent="1017" relname="joint"/>
<group id="1026" type="span" parent="1017" relname="joint"/>
<group id="1027" type="span" parent="26" relname="elaboration"/>
<group id="1029" type="span" parent="1017" relname="joint"/>
<group id="1030" type="multinuc" parent="1029" relname="span"/>
<group id="1031" type="span" parent="1030" relname="joint"/>
<group id="1033" type="span" parent="1030" relname="joint"/>
<group id="1034" type="span" parent="1030" relname="joint"/>
<group id="1035" type="span" parent="1034" relname="span"/>
<group id="1036" type="span" parent="1035" relname="span"/>
<group id="1037" type="multinuc" parent="1036" relname="span"/>
<group id="1038" type="multinuc" parent="1037" relname="joint"/>
<group id="1039" type="span" parent="1038" relname="same_unit"/>
<group id="1042" type="span" parent="1037" relname="joint"/>
<group id="1043" type="span" parent="1045" relname="concession"/>
<group id="1044" type="span" parent="1043" relname="span"/>
<group id="1045" type="multinuc" parent="1042" relname="span"/>
<group id="1046" type="span" parent="1045" relname="same_unit"/>
<group id="1047" type="span" parent="1046" relname="span"/>
<group id="1048" type="span" parent="1047" relname="span"/>
<group id="1050" type="span" parent="1037" relname="joint"/>
<group id="1051" type="span" parent="50" relname="means"/>
<group id="1052" type="multinuc" parent="1051" relname="span"/>
<group id="1053" type="span" parent="1052" relname="same_unit"/>
<group id="1054" type="span" parent="1052" relname="elaboration"/>
<group id="1056" type="multinuc" parent="1037" relname="joint"/>
<group id="1057" type="span" parent="1056" relname="same_unit"/>
<group id="1058" type="multinuc" parent="1056" relname="same_unit"/>
<group id="1059" type="span" parent="1058" relname="same_unit"/>
<group id="1060" type="span" parent="1058" relname="same_unit"/>
<group id="1062" type="span" parent="1037" relname="joint"/>
<group id="1063" type="span" parent="1064" relname="preparation"/>
<group id="1064" type="multinuc" parent="1062" relname="span"/>
<group id="1066" type="span" parent="1064" relname="joint"/>
<group id="1068" type="span" parent="1064" relname="joint"/>
<group id="1069" type="span" parent="68" relname="elaboration"/>
<group id="1072" type="span" parent="1064" relname="joint"/>
<group id="1074" type="span" parent="1064" relname="joint"/>
<group id="1075" type="multinuc" parent="1074" relname="span"/>
<group id="1076" type="span" parent="1075" relname="same_unit"/>
<group id="1078" type="span" parent="1064" relname="joint"/>
<group id="1079" type="span" parent="1078" relname="span"/>
<group id="1080" type="span" parent="1064" relname="joint"/>
<group id="1081" type="span" parent="81" relname="means"/>
	</body>
</rst>
